FDA Pauses U.S. Enrollment in Myotonic Dystrophy Trial After Serious Adverse Event
The FDA has placed a partial hold on U.S. enrollment in a Phase 2 trial of del-desiran for myotonic dystrophy type 1, citing preclinical mouse data showing blood pressure drops not seen in humans, following a serious adverse event in earlier testing.